Published in J Biol Chem on May 09, 2007
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin αvβ₃. Blood (2011) 1.68
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc Natl Acad Sci U S A (2008) 1.49
The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol (2009) 1.46
Role of Epac1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function. Mol Biol Cell (2008) 1.34
Rap1a is a key regulator of fibroblast growth factor 2-induced angiogenesis and together with Rap1b controls human endothelial cell functions. Mol Cell Biol (2008) 1.18
The adenylyl cyclase activity of anthrax edema factor. Mol Aspects Med (2009) 1.15
New insights into the biological effects of anthrax toxins: linking cellular to organismal responses. Microbes Infect (2011) 1.14
Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed) (2011) 1.10
Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration. Am J Physiol Heart Circ Physiol (2008) 1.06
Lung epithelial injury by B. anthracis lethal toxin is caused by MKK-dependent loss of cytoskeletal integrity. PLoS One (2009) 1.06
Suppression of T-lymphocyte activation and chemotaxis by the adenylate cyclase toxin of Bordetella pertussis. Infect Immun (2008) 0.97
Anthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta. Infect Immun (2009) 0.95
Anthrax toxin protective antigen--insights into molecular switching from prepore to pore. Protein Sci (2012) 0.92
Anthrax edema toxin modulates PKA- and CREB-dependent signaling in two phases. PLoS One (2008) 0.90
Bacillus anthracis edema toxin suppresses human macrophage phagocytosis and cytoskeletal remodeling via the protein kinase A and exchange protein activated by cyclic AMP pathways. Infect Immun (2009) 0.88
AB toxins: a paradigm switch from deadly to desirable. Toxins (Basel) (2010) 0.88
Bacillus anthracis edema factor substrate specificity: evidence for new modes of action. Toxins (Basel) (2012) 0.87
Cytoskeleton as an emerging target of anthrax toxins. Toxins (Basel) (2012) 0.86
Exchange protein directly activated by cAMP encoded by the mammalian rapgef3 gene: Structure, function and therapeutics. Gene (2015) 0.85
Exchange protein activated by cAMP (Epac) induces vascular relaxation by activating Ca2+-sensitive K+ channels in rat mesenteric artery. J Physiol (2013) 0.84
Distinct gene-expression profiles characterize mammary tumors developed in transgenic mice expressing constitutively active and C-terminally truncated variants of STAT5. BMC Genomics (2009) 0.84
Cellular and physiological effects of anthrax exotoxin and its relevance to disease. Front Cell Infect Microbiol (2012) 0.84
pH effects on binding between the anthrax protective antigen and the host cellular receptor CMG2. Protein Sci (2012) 0.83
A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer. PLoS One (2012) 0.81
Anthrax edema toxin impairs clearance in mice. Infect Immun (2011) 0.81
Bacillus anthracis-derived edema toxin (ET) counter-regulates movement of neutrophils and macromolecules through the endothelial paracellular pathway. BMC Microbiol (2012) 0.80
Tumor Targeting and Drug Delivery by Anthrax Toxin. Toxins (Basel) (2016) 0.80
Emergence of anthrax edema toxin as a master manipulator of macrophage and B cell functions. Toxins (Basel) (2010) 0.79
Micropatterned macrophage analysis reveals global cytoskeleton constraints induced by Bacillus anthracis edema toxin. Infect Immun (2015) 0.78
Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling. Cell Adh Migr (2014) 0.77
A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection. Toxins (Basel) (2017) 0.75
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature (2002) 3.67
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc (2010) 3.44
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature (2006) 3.21
Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J (2009) 3.11
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol (2011) 2.88
Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem (2003) 2.66
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol (2004) 2.58
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol (2005) 2.45
Rap1 promotes cell spreading by localizing Rac guanine nucleotide exchange factors. J Cell Biol (2004) 2.27
Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem (2003) 2.24
tRNA over-expression in breast cancer and functional consequences. Nucleic Acids Res (2009) 2.08
Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J Biol Chem (2002) 2.06
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res (2005) 1.97
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol (2012) 1.96
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol (2010) 1.92
Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med (2005) 1.90
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol (2010) 1.90
Rap1 GTPase inhibits leukocyte transmigration by promoting endothelial barrier function. J Biol Chem (2005) 1.84
Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'. Nat Chem Biol (2008) 1.74
Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell (2006) 1.71
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer (2012) 1.70
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One (2010) 1.69
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
Cyclic AMP-Rap1A signaling activates RhoA to induce α(2c)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells. Am J Physiol Cell Physiol (2012) 1.62
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J (2011) 1.60
Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J Immunol (2005) 1.59
Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines. Nat Neurosci (2009) 1.58
Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol (2007) 1.56
Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J (2005) 1.53
The expanding role of systemic therapy in head and neck cancer. J Clin Oncol (2004) 1.50
Cool-1/βPIX functions as a guanine nucleotide exchange factor in the cycling of Cdc42 to regulate insulin secretion. Am J Physiol Endocrinol Metab (2011) 1.50
Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem (2005) 1.48
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 1.46
Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell (2005) 1.45
Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol (2013) 1.44
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res (2009) 1.43
Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem (2003) 1.43
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity (2003) 1.43
Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem (2007) 1.41
Antiinflammatory cAMP signaling and cell migration genes co-opted by the anthrax bacillus. Proc Natl Acad Sci U S A (2008) 1.39
Cause-related marketing: the uneasy alliance between altruism and corporate greed. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 1.39
Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res (2008) 1.38
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res (2013) 1.38
Chemoattractant-stimulated Rac activation in wild-type and Rac2-deficient murine neutrophils: preferential activation of Rac2 and Rac2 gene dosage effect on neutrophil functions. J Immunol (2002) 1.37
Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat Biotechnol (2004) 1.37
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb Pathog (2007) 1.36
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One (2010) 1.35
Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One (2007) 1.32
Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme. Biochemistry (2008) 1.31
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer (2012) 1.31
Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins. EMBO J (2002) 1.28
Cellular functions and X-ray structure of anthrolysin O, a cholesterol-dependent cytolysin secreted by Bacillus anthracis. J Biol Chem (2009) 1.25
Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets (2008) 1.24
The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane. J Biol Chem (2005) 1.24
Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J Biol Chem (2003) 1.24
Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin. EMBO J (2005) 1.22
ERK8, a new member of the mitogen-activated protein kinase family. J Biol Chem (2002) 1.21
Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem (2009) 1.20
Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res (2006) 1.20
RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. J Biol Chem (2002) 1.19
Rap1a is a key regulator of fibroblast growth factor 2-induced angiogenesis and together with Rap1b controls human endothelial cell functions. Mol Cell Biol (2008) 1.18
Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme. J Mol Biol (2009) 1.17
Calcium dependence of the interaction between calmodulin and anthrax edema factor. J Biol Chem (2003) 1.16
Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am J Pathol (2011) 1.16
Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J (2010) 1.16
An integrated view of cyclin E function and regulation. Cell Cycle (2012) 1.15
AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res (2005) 1.14
The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition. Biochem Biophys Res Commun (2006) 1.14
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res (2010) 1.13
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol (2006) 1.13
The Rac effector p67phox regulates phagocyte NADPH oxidase by stimulating Vav1 guanine nucleotide exchange activity. Mol Cell Biol (2006) 1.13
Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front Biosci (2007) 1.11
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) (2010) 1.10
Cytidylyl and uridylyl cyclase activity of bacillus anthracis edema factor and Bordetella pertussis CyaA. Biochemistry (2010) 1.09
Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor. Proc Natl Acad Sci U S A (2010) 1.08
Nonheritable cellular variability accelerates the evolutionary processes of cancer. PLoS Biol (2012) 1.06
Rac2, a hematopoiesis-specific Rho GTPase, specifically regulates mast cell protease gene expression in bone marrow-derived mast cells. Mol Cell Biol (2002) 1.06
Network of mutually repressive metastasis regulators can promote cell heterogeneity and metastatic transitions. Proc Natl Acad Sci U S A (2014) 1.05
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res (2011) 1.05
Tumor suppressor maspin is up-regulated during keratinocyte senescence, exerting a paracrine antiangiogenic activity. Cancer Res (2004) 1.05
E-cadherin dis-engagement activates the Rap1 GTPase. J Cell Biochem (2008) 1.05
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet (2005) 1.04
Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol Pharmacol (2008) 1.04